Dolutegravir-lamivudine (Dovato, ViiV), INSTI/NRTI, Bictegravir-emtricitabine-TAF (Biktarvy, Gilead), INSTI/NRTI, .
(Erleada). Enzalutamide. (Xtandi). ↓ INSTI. ↓ INSTI. ↓ NNRTI. ↓ NNRTI. ↓ PI. ↓ TAF. CHEMOTHERAPY. Page 3. Mechanism of Drug Interactions, Management and
by SJ Smith 2024 Cited by 24Both DTG and BIC potently inhibit most INSTI-resistant IN mutants selected by the INSTIs raltegravir (RAL) and elvitegravir (EVG).
INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg orally twice a day Comments:-Rilpivirine dose is 25 mg orally once a day for patients switching to this drug plus rilpivirine.
2 NRTIs combined with an INSTI: NRTIs (Nucleoside Reverse Transcriptase Inhibitors) and INSTIs (Integrase Strand Transfer Inhibitors) are both
- If neither a fully active PI or second-generation INSTI drugs used and number and types of drug-resistant mutations that are present.
by BN Harding 2024 Cited by 7These findings suggest INSTI use may increase the risk of anaemia. If confirmed, screening for anaemia development in users of INSTIs may be beneficial.
Considering the increasing interest in INSTIs for HIV-1 treatment, we focus our review on the retroviral integrase, development of INSTIs and their mode of action. We also discuss each of the INSTI drugs, including potential drug resistance and known side effects.
Background Global antiretroviral therapy has entered a new era. Integrase strand transfer inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) treatment. Because INSTI has high antiviral efficacy, rapid virus inhibition, and good tolerance. However, INSTIs may increase the risk of obesity. Each INSTI has its unique impact on weight gain in patients with
Comments